Barinthus Biotherapeutics (BRNS) Change in Accured Expenses (2020 - 2026)

Barinthus Biotherapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 202.54% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 205.79% YoY), and the FY2025 full-year result was -$3.8 million, down 931.8% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $2.6 million, up from -$453000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.6 million in Q3 2022, with the low at -$4.3 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged $117235.3 across 5 years, with a median of -$453000.0 in 2025.
• The largest YoY upside for Change in Accured Expenses was 2720.37% in 2022 against a maximum downside of 479.63% in 2022.
• Barinthus Biotherapeutics' Change in Accured Expenses stood at -$4.3 million in 2022, then advanced by 24.89% to -$3.2 million in 2023, then surged by 161.22% to $2.0 million in 2024, then sank by 122.83% to -$453000.0 in 2025, then surged by 670.86% to $2.6 million in 2026.
• The last three Change in Accured Expenses figures came in at $2.6 million (Q1 2026), -$453000.0 (Q4 2025), and -$573000.0 (Q3 2025), per Business Quant data.